title: Sitagliptin for Type 2 diabetes: a 2015 update.
abstract: Sitagliptin, a dipeptidyl peptidase 4 inhibitor, was the first in its class to receive approval from the US FDA in 2006 for the treatment of Type 2 diabetes mellitus. It has been evaluated in numerous clinical trials and has several attractive features as an antidiabetic agent, including a low risk for hypoglycemia, a neutral effect on weight, and an ability to be used in chronic kidney disease and more. This article provides an up-to-date discussion of the pharmacokinetics/pharmacodynamics, clinical efficacy, safety and tolerability of sitagliptin.
authors.affiliation: Emory University School of Medicine, Medicine/Endocrinology, 1303 Woodruff Memorial Research Building,101 Woodruff Circle, Suite 1303, Atlanta, GA 30322, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Lee
authors.forename: Mary K
authors.initials: MK
authors.lastname: Rhee
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D000068900:Sitagliptin Phosphate
keywords: Type 2 diabetes; diabetes mellitus; dipeptidyl peptidase 4 inhibitor; incretin-based therapy; sitagliptin